Multicenter studies promote collaboration among researchers and institutions that leads to advancements in pediatric care. Johns Hopkins All Children’s multicenter studies include:
The purpose of this study is to evaluate the safety, dose-requirements, and exploratory efficacy of twice-daily subcutaneous enoxaparin as in-hospital venous thromboembolism (VTE) prophylaxis in children (birth to 18 years) hospitalized with signs and/or symptoms of SARS-CoV-2 infection (i.e., COVID-19) including COVID-19 multisystem inflammatory syndrome (CMIS).
Johns Hopkins Alliance for a Healthier World COVID-19
Characterizing the social, economic and health impact of COVID-19 on vulnerable families.A Health Equity Perspective study will support the implementation of a novel family-impact index assessing eight different domains of family function as impacted by COVID-19 across three racially-ethnic and geographically diverse sites (Baltimore MD, Chapel Hill NC, St. Petersburg Florida). These data will allow for an in-depth understanding of the unique needs of families during the pandemic and will critically inform future interventions at the local, regional and national level.
Johns Hopkins All Children’s Hospital is the Clinical Coordinating Center for the Kids-DOTT trial, a definitive multicenter randomized clinical trial to establish the duration of anticoagulation for venous thrombosis in children.
The study will also investigate the use of certain blood thinners in children. The study includes Central Investigational Pharmacy and Central Biorepository roles.
Understanding why some children stay healthy throughout their lives, while others develop serious illnesses or learning problems is essential in developing prevention programs to help keep all children healthy.
The PREDICT research study works with children and families to track and evaluate their health and development over time. Understanding what protects children from developing certain conditions and illnesses will help develop future treatment and prevention programs.